Hypertension Diagnostics Return On Asset vs. EBITDA

Based on Hypertension Diagnostics' profitability indicators, Hypertension Diagnostics may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in April. Profitability indicators assess Hypertension Diagnostics' ability to earn profits and add value for shareholders.
For Hypertension Diagnostics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Hypertension Diagnostics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Hypertension Diagnostics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Hypertension Diagnostics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Hypertension Diagnostics over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
Please note, there is a significant difference between Hypertension Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hypertension Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hypertension Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Hypertension Diagnostics EBITDA vs. Return On Asset Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Hypertension Diagnostics's current stock value. Our valuation model uses many indicators to compare Hypertension Diagnostics value to that of its competitors to determine the firm's financial worth.
Hypertension Diagnostics is one of the top stocks in return on asset category among its peers. It also is one of the top stocks in ebitda category among its peers totaling about  240,966,667  of EBITDA per Return On Asset. Comparative valuation analysis is a catch-all model that can be used if you cannot value Hypertension Diagnostics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Hypertension Diagnostics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Hypertension EBITDA vs. Return On Asset

Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Hypertension Diagnostics

Return On Asset

 = 

Net Income

Total Assets

 = 
3.0E-4
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Hypertension Diagnostics

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
72.29 K
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Hypertension EBITDA Comparison

Hypertension Diagnostics is currently under evaluation in ebitda category among its peers.

Hypertension Diagnostics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Hypertension Diagnostics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Hypertension Diagnostics will eventually generate negative long term returns. The profitability progress is the general direction of Hypertension Diagnostics' change in net profit over the period of time. It can combine multiple indicators of Hypertension Diagnostics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Hypertension Diagnostics, Inc. designs, develops, manufactures, and markets proprietary noninvasive medical devices that detect subtle changes in the elasticity of arteries in the United States and internationally. Hypertension Diagnostics, Inc. was founded in 1988 and is based in Richmond Hill, Canada. Hypertension Diag operates under Shell Companies classification in the United States and is traded on OTC Exchange.

Hypertension Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Hypertension Diagnostics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Hypertension Diagnostics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Hypertension Diagnostics' important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in Hypertension Diagnostics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Risk-Return Analysis Now

   

Risk-Return Analysis

View associations between returns expected from investment and the risk you assume
All  Next Launch Module

Use Investing Themes to Complement your Hypertension Diagnostics position

In addition to having Hypertension Diagnostics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Adviser Favorites Thematic Idea Now

Adviser Favorites
Adviser Favorites Theme
Financial advisors frequently recommend that individuals diversify their investment portfolios with a mix of different types of stocks. These can include blue-chip stocks, growth stocks, and dividend stocks. The Adviser Favorites theme has 14 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Adviser Favorites Theme or any other thematic opportunities.
View All  Next Launch
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Other Consideration for investing in Hypertension Pink Sheet

If you are still planning to invest in Hypertension Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hypertension Diagnostics' history and understand the potential risks before investing.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Equity Valuation
Check real value of public entities based on technical and fundamental data
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios